Garetatug Rezetecan

瑞康戈芮妥塔单抗

Report date: 2026/05/22 20:01:29

Base Information

Drug NameGaretatug Rezetecan
Drug Alias NameSHR-1904 Claudin 18.2 ADCSHR-A1904SHR-A-1904SHR-1904
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > Cleavable peptide linker
Mechanisms of ActionAnti-CLDN18DNA topoisomerase I inhibitors
TargetsClaudin-18 splice variant 2DNA topoisomerase I
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursPancreatic Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaSwitzerland +[5] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShanghai Hengrui Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Suncadia Medicine Co LtdLuzsana Biotechnology Europe AGBeijing GoBroad Hospital +[9] 
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursPancreatic Neoplasms +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A